Viatris (VTRS) Company Report

Mapi Pharma will present new safety and efficacy data from its GA Depot Phase II study in primary progressive multiple sclerosis (PPMS) at ACTRIMS Forum 2026, February 5–7 in San Diego.
The open-label Phase IIa trial enrolled 30 PPMS patients treated with 25 mg (n=10) or 40 mg (n=20) intramuscular GA Depot every 28 days for up to three years.
Results showed stable or improved mean EDSS (from 5.1 to 4.5 at three years) and a 96.6% confirmed disability progression–free rate; 69% of patients had no evidence of progression.
GA Depot was generally well tolerated, with most adverse events (81.6%) being mild (injection site reactions, asthenia, fever), and lower AE rates at the 25 mg dose.
Following Israeli and EU GMP approval, a Phase III PPMS study is planned for 2026, with potential commercial launch in relapsing MS in 2027 under Viatris’ exclusive license.

4 days ago

Press Release

Viatris launches Inpefa in UAE

VTRS

Product Launch

Viatris launched Inpefa (sotagliflozin) in the UAE, the first country in its territories to commercialize the dual SGLT1/2 inhibitor for heart failure treatment.
Inpefa, approved to reduce cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease or other cardiovascular risk factors, is the first and only dual SGLT1/2 inhibitor for heart failure.
Approval was based on Phase 3 trials: SOLOIST-WHF showed a 33% reduction in the composite risk of heart failure hospitalization, urgent visits and cardiovascular death (up to 51% when initiated pre-discharge); SCORED showed a 25% reduction in the same endpoint; MACE was reduced by 23%, MI by 32% and stroke by 34%.
Viatris plans additional launches over the next several years and has submitted regulatory filings in Canada, Australia and Mexico to expand global access.

Jan 20, 2026, 11:59 AM

Press Release

Viatris outlines 2026 growth strategy at J.P. Morgan Healthcare Conference

VTRS

Product Launch

Share Buyback

M&A

Viatris reported $14.1 billion in 2025 revenue, $4.1 billion EBITDA, and $2.2 billion in free cash flow in the last 12 months, serving over 1 billion patients in 165 countries.
The base generics and established brands business has stabilized with 1–2% revenue growth over the past eight to ten quarters, and management expects to drive mid-single-digit revenue growth in 2026 through planned launches and accretive in-market business development.
A robust pipeline and launch slate is set for 2026, including fast-acting meloxicam, sotagliflozin, pitolisant and Spidifen in Japan, Effexor GAD, plus Phase 3 readouts for cenerimod and selatogrel expected late 2026/early 2027.
An enterprise-wide strategic review aims to optimize procurement, marketing and development, delivering net savings to the bottom line; cash flow will be allocated roughly 50/50 between dividends/share buybacks and business development.

Jan 13, 2026, 5:00 PM

Transcript

Viatris outlines 2026 growth strategy at J.P. Morgan Healthcare Conference

VTRS

Guidance Update

Product Launch

M&A

Over the past 12 months, Viatris delivered $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow across 165 countries with 1,400 products.
Management returned over $1 billion to shareholders through dividends and share buybacks and initiated an Enterprise-Wide Strategic Review to streamline operations and reinvest savings.
The company expects to shift to mid-single-digit revenue growth in 2026, supported by upcoming launches and net savings from the strategic review beginning to drop to the bottom line.
Key 2026 launches include sotagliflozin, fast-acting meloxicam, low-dose estrogen patch, and in Japan: Spidifen, Pitolisant, Effexor GAD, plus an eye-care treatment for presbyopia.
Viatris is targeting $500 million–$1 billion peak-revenue assets via ~60 regional deals annually, with emphasis on accretive U.S. in-market and Japan business development.

Jan 13, 2026, 5:00 PM

Transcript

Viatris outlines 2026 strategy and pipeline at JPM Healthcare Conference

VTRS

Product Launch

M&A

Share Buyback

Viatris reported $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow for 2025, operating in 165 countries and serving over 1 billion patients annually.
The company achieved 5 of 6 positive Phase 3 readouts in 2025 and advanced key pipeline assets (Cenerimod, Selatogrel, Lucerastat), with planned 2026 launches of sotagliflozin, fast-acting meloxicam, Pitolisant, Spidifen, and Effexor GAD.
An Enterprise-Wide Strategic Review completed in 2025 aims to optimize the organizational structure, with significant cost savings expected to begin flowing through in 2026 and support mid-single-digit revenue growth.
Viatris executed 60 regional business development deals in 2025, is targeting accretive U.S. assets ($500 million–$1 billion peak sales), expanded its Japan portfolio via the Oculus acquisition, and plans a 50/50 split of free cash flow between shareholder returns and M&A over the next 3–5 years.
Remediation at the Indore manufacturing facility is ~90% complete; FDA reinspection timing is pending, but built-in redundancies should limit operational volatility in 2026.

Jan 13, 2026, 5:00 PM

Transcript

Viatris outlines 2025 financial results and 2026 strategic priorities

VTRS

Product Launch

Guidance Update

12 months ended September 30, 2025: Total revenues of $14.1 billion, adjusted EBITDA of $4.1 billion, adjusted EPS of $2.32, and free cash flow ex-transaction costs of $2.2 billion.
Global footprint: operations in 165+ countries, 26 manufacturing facilities, ~1,400 approved molecules, serving ~1 billion patients annually.
Achieved key 2025 milestones: completed five positive Phase 3 readouts, over $1 billion returned to shareholders, and acquisition of Aculys Pharma in Japan.
2026 strategic setup: anticipated launches (e.g., sotagliflozin in H1 2026, low-dose estrogen patch in H2 2026), enterprise-wide cost savings, and pipeline milestones for cenerimod and selatogrel.

Jan 13, 2026, 5:00 PM

Presentation

vVARDIS presents drill-free early cavity treatment at 2026 J.P. Morgan Healthcare Conference

VTRS

Product Launch

New Projects/Investments

vVARDIS founders Drs. Haley and Goly Abivardi showcased Curodont™, a drill-free early cavity treatment—with over 2 million teeth treated in 24 months—at the 2026 J.P. Morgan Healthcare Conference.
Emphasized recognition by Jamie Dimon at the 2025 event and vVARDIS’ status as the fastest-growing dental product in the U.S. preventive category.
Launched the “Save Teeth Save Lives” global cavity awareness campaign, symbolized by a turquoise ribbon, to promote early, non-invasive cavity intervention.
Highlighted recent momentum with $85 million in funding from OrbiMed and expanded partnership with Henry Schein, supporting Curodont’s rollout in 12 percent of U.S. dental offices.
Earned Dental Advisor’s 2026 Innovative Company of the Year award and Research Award for Curodont Repair Fluoride Plus.

Jan 12, 2026, 5:35 PM

Press Release

Viatris provides pipeline update on four regulatory milestones

VTRS

Product Launch

New Projects/Investments

FDA approval of generic octreotide acetate LAR depot injectable suspension for acromegaly and carcinoid tumour indications
FDA acceptance of NDA for a once-weekly low-dose estrogen patch (150 mcg norelgestromin/17.5 mcg ethinyl estradiol) with a PDUFA target date of July 30, 2026
FDA clearance of IND for MR-146 AAV gene therapy in neurotrophic keratopathy, with a Phase 1/2 CORVITA trial planned in H1 2026
PMDA acceptance of J-NDA for pitolisant in obstructive sleep apnea syndrome; narcolepsy J-NDA submission expected by year-end 2025

Dec 18, 2025, 11:59 AM

Press Release

Viatris announces monetization of Biocon Biologics stake

VTRS

M&A

Viatris will sell its convertible preferred equity in Biocon Biologics for $815 million total consideration: $400 million in cash and $415 million in newly issued Biocon Limited shares.
The agreement accelerates biosimilars non-compete restrictions, which will lapse immediately for ex-U.S. markets and in November 2026 for U.S. markets.
The transaction is expected to close in Q1 2026, subject to customary closing conditions.
Citi is acting as financial advisor, with Cravath, Swaine & Moore LLP and Khaitan & Co. as legal advisors to Viatris.

Dec 8, 2025, 12:00 PM

8-K

Viatris to monetize Biocon Biologics stake

VTRS

M&A

Convertible Preferred Issuance

Viatris enters agreements to sell its convertible preferred equity stake in Biocon Biologics for $815 million total consideration ($400 million cash + $415 million Biocon shares).
Shares are subject to a six-month lock-up and will trade on the National Stock Exchange of India.
The deal accelerates expiration of biosimilars non-compete restrictions, effective at close outside the U.S. and in November 2026 for U.S. markets.
The transaction is expected to close in Q1 2026, pending satisfaction of closing conditions.